研究单位：[1]Shanghai Pharmaceuticals Holding Co.,Ltd[2]Anyang Cancer Hospital,Anyang,China[3]The First Affiliated Hospital of Bengbu Medical University,Bengbu,China[4]Hunan cancer hospital,Changsha,China[5]Sichuan Cancer Hospital,Chengdu,China[6]Dongguan People's Hospital,Dongwan,China[7]Fujian Cancer Hospital,Fuzhou,China[8]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,China[9]The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,China[10]Harbin Medical University Cancer Hospital,Ha'erbin,China[11]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,China[12]The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,China[13]Shandong cancer hospital,Jinan,China[14]Jiangxi cancer hospital,Nanchang,China[15]Guangxi Medical University Affiliated Cancer Hospital,Nanning,China[16]Shanghai East Hospital,Shanghai,China[17]Shanghai Ninth People's Hospital,Shanghai,China[18]Liaoning Cancer Hospital,Shenyang,China[19]Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center,Shenzhen,China[20]Shanxi Cancer Hospital,Taiyuan,China[21]Tianjin cancer hospital,Tianjin,China[22]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China[23]Henan cancer hospital,Zhengzhou,China
研究目的：
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
